Medicure Report issue

For profit Phase 2 Phase 3
Founded: Winnipeg Canada (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2004
NCT00157716
First Marketed Drug
1998
tirofiban (aggrastat)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Medicure | MEDICURE

Active Ingredients

Marketed Drugs (3)

nitroprusside (nipride) (2018)

pitavastatin (livalo) (2017)

tirofiban (aggrastat) (1998)

Drugs in Phase 3 Trials (3)

pyridoxal phosphate anhydrous (1 trial)

pyridoxine (4 trials)

tirofiban (aggrastat) (3 trials)

Drugs in Phase 2 Trials (1)

eptifibatide (integrilin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Angina, Unstable (Phase 3)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dyskinesias (Phase 2)

Hypertension (Phase 2)

Infarction (Phase 3)

Ischemia (Phase 3)

Metabolic Syndrome (Phase 2)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Renal Insufficiency (Phase 1)

Reperfusion Injury (Phase 3)

Tardive Dyskinesia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4